Nexalin Technology, Inc.
NXLNasdaqHealthcare · Electromedical & Electrotherapeutic Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
| Revenue | $301,647 | $168,721 | $110,748 | $1.3M | $144,065 |
| Operating income | −$8.4M | −$7.8M | −$5.7M | −$1.8M | −$6.0M |
| Net income | −$8.2M | −$7.6M | −$4.6M | −$1.7M | −$6.1M |
| Total assets | $4.6M | $4.2M | $3.6M | $7.4M | $753,698 |
| Total liabilities | $887,333 | $546,694 | $425,281 | $2.0M | $2.4M |
| Equity | $3.7M | $3.7M | $3.2M | $5.5M | −$1.7M |
| EPS (diluted) | $-0.50 | $-0.83 | $-0.63 | $-0.30 | — |
| Shares out. | 13.3M | 7.4M | 7.3M | 7.3M | 4.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −2781.7%
- Net margin
- −2725.8%
- Return on equity
- −219.4%
- Return on assets
- −177.4%
- Return on capital (ROCE)
- −223.9%
- Liabilities / assets
- 19.1%
- Debt / equity
- 0.24×
- Book value / share
- $0.28
- Revenue growth (YoY)
- 78.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -68.21distress
- Accruals / assets
- −70.4%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Osser Leonard10% owner | Sep 29, 2025 | Grant | 83,333 | $0.00 |
| Owens DavidOfficer — Chief Medical Officer | Sep 29, 2025 | Grant | 36,459 | $0.00 |
| Hu BenDirector | Sep 29, 2025 | Grant | 36,459 | $0.00 |
| Kazden AlanDirector | Sep 29, 2025 | Grant | 36,459 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 607,378 | 6.1 | +6.0% |
| Apr 30, 2026 | 573,186 | 3.7 | -4.7% |
| Apr 15, 2026 | 601,117 | 1.0 | +24.7% |
| Mar 31, 2026 | 481,971 | 3.8 | +9.4% |
| Mar 13, 2026 | 440,670 | 4.1 | -26.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Unregistered equity sale · Other material eventMay 19, 2026
- Entered a material agreement · Regulation FD disclosureApr 22, 2026
- Regulation FD disclosureFeb 25, 2026
- Delisting / listing-standard notice · Other material eventJan 23, 2026
- Other material eventDec 5, 2025
- Entered a material agreementOct 15, 2025
- Other material eventSep 22, 2025
- Director / officer changeAug 4, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.